We are live on ! Find out more
ELVN icon

Enliven Therapeutics
ELVN

40 hedge funds and large institutions have $92.6M invested in Enliven Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

21% more funds holding

Funds holding: 33 → 40 (+7)

1.09% less ownership

Funds ownership: 16.74% → 15.65% (-1.1%)

64% less capital invested

Capital invested by funds: $257M → $92.6M (-$164M)

Holders
40
Holders Change
+7
Holders Change %
+21.21%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
13
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$3.99M
2
Two Sigma Investments
Two Sigma Investments
New York
+$647K
3
Bank of America
Bank of America
North Carolina
+$569K
4
Walleye Capital
Walleye Capital
New York
+$428K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$255K

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$7.95M
2
DM
Deerfield Management
New York
-$6.33M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.63M
4
SFI
Susquehanna Fundamental Investments
Pennsylvania
-$206K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$104K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
26
California State Teachers Retirement System (CalSTRS)
California
$98K – – –
Deutsche Bank
27
Deutsche Bank
Germany
$96K +$73.1K +1,439 +102%
JF
28
Jump Financial
Illinois
$84K +$127K +2,500 New
New York State Common Retirement Fund
29
New York State Common Retirement Fund
New York
$54K – – –
Wells Fargo
30
Wells Fargo
California
$20K -$19.5K -383 -40%
TRCT
31
Tower Research Capital (TRC)
New York
$15K -$39.1K -769 -63%
UBS Group
32
UBS Group
Switzerland
$14K +$6.66K +131 +47%
Legal & General Group
33
Legal & General Group
United Kingdom
$8K +$1.52K +30 +14%
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$7K +$5.49K +108 +106%
Citigroup
35
Citigroup
New York
$4K -$11.5K -227 -64%
AIP
36
Ameritas Investment Partners
Nebraska
$4K – – –
Bank of Montreal
37
Bank of Montreal
Ontario, Canada
$2K -$12.3K -242 -80%
PAM
38
Panagora Asset Management
Massachusetts
$1K – – –
Walleye Capital
39
Walleye Capital
New York
$284 +$428K +8,426 New
AIG
40
American International Group
New York
$38 +$152 +3 +0.3%
RSCM
41
Rock Springs Capital Management
Maryland
– -$7.95M -90,125 Closed
SFI
42
Susquehanna Fundamental Investments
Pennsylvania
– -$206K -2,337 Closed
SO
43
STRS Ohio
Ohio
– -$28K -325 Closed
1
2

ELVN Hedge Fund Activity: Q1 2021 in Review

40 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2021, worth a combined $92.6M — down 64% from $257M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ELVN positions and 3 closed out — a net gain of 7 holders — while 13 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.99M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $7.95M sold.

  • 40 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2021, up from 33 in Q4 2020.
  • Funds reported $92.6M of Enliven Therapeutics stock for Q1 2021, down 64% quarter-over-quarter.
  • 10 funds opened new Enliven Therapeutics positions in Q1 2021 and 3 closed out, a net change of +7 holders.
  • The largest Enliven Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $3.99M added.
  • The largest Enliven Therapeutics seller in Q1 2021 was Rock Springs Capital Management, an estimated $7.95M sold.

Based on aggregated 13F filings for Q1 2021.